Status:
COMPLETED
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University
Conditions:
Type 2 Diabetic Nephropathy
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of the real-world observational prospective study is to access the renoprotective effects of dulaglutide as well as to explore corresponding mechanisms in patients with Type 2 Diabetic Nep...
Detailed Description
Related studies have found that Glucagon-like peptide-1 (GLP-1) receptors are localized on a variety of tissues and cell types in addition to pancreatic β-cells, and GLP-1 and GLP-1 receptor agonists ...
Eligibility Criteria
Inclusion
- All adults aged 18 and above
- No minors involved in the study
- Diabetic Nephropathy defined as a urinary albumin-to-creatinine ratio ≥30 mg/g at least twice in three measurements within a period of 3-6 months
Exclusion
- Patients with other types of kidney disease
- Urinary tract infection
- Type 1 diabetes
Key Trial Info
Start Date :
October 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06182891
Start Date
October 30 2021
End Date
October 30 2023
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology
Xuzhou, Jiangsu, China, 221002